Emerging Company Profile
InterVenn: liquid biopsy diagnostics based on glycoproteins
InterVenn builds on research by scientific founders Bertozzi, Lebrillo to develop glycoproteomic cancer diagnostics
InterVenn, building on research by scientific co-founders Carolyn Bertozzi and Carlito Lebrilla, is applying AI to develop blood-based glycoproteomic cancer diagnostics.
InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.
The company announced Monday that it raised a $34 million series B round led by Anzu Partners and